Clinical question
What are the benefits and harms of antipsychotics for agitation in dementia?
Bottom line
Antipsychotics provide little improvement over placebo on agitation scales. However, a 50% improvement in behaviour occurs in about 46% of those taking antipsychotics versus about 33% taking placebo. Harms are serious (eg, 1 increased death in 80 over 3 months) and common. Antipsychotics should be reserved for severe aggression, and withdrawal should be attempted as soon as possible.
Evidence
Evidence includes 6 systematic reviews (5 to 16 RCTs of 856 to 5110 patients that lasted 10 to 12 weeks).1–6 Results are statistically significant unless indicated otherwise.
Placebo had large effects (eg, 11-point increase on a 144-point scale—a clinically meaningful difference).7
Studies of atypical antipsychotics revealed the following:
-Mean improvement on multiple scales was trivial (eg, 3 on a 144-point scale [not likely clinically meaningful]).1–3
-Individual antipsychotics had generally similar results.2,5
-Some patients attained 50% improvement on scales (eg, 46% with risperidone vs 33% with placebo, number needed to treat [NNT] = 8).4
-Harms included stopping owing to adverse events (number needed to harm [NNH] = 13 to 39).2 Serious harms included death (NNH = 77 to 84)1,4 and cerebrovascular events (NNH = 48 to 104).1,2,4
-Mini-Mental State Examination score was 0.73 points worse (statistically, not clinically, significant).4
-Other harms were somnolence (NNH = 7 to 11), gait abnormalities (NNH = 11 to 20), extrapyramidal symptoms (NNH = 16 to 44), and peripheral edema (NNH = 20 to 25).1,2,4
First-generation antipsychotics (eg, haloperidol) appear to have similar rates of harms but inconsistent benefits.6
Context
Cholinesterase inhibitors, selective serotonin reuptake inhibitors, trazodone, and valproate provide no meaningful improvement in agitation.8–11
-Benzodiazepines might approach antipsychotics in efficacy for agitation but also have harms.12
Stopping antipsychotics might reduce death (NNT = 4 at 2 years) with little effect on neuropsychiatric symptoms.13
Implementation
Medical, psychological, and environmental triggers should be assessed and targeted in patients with agitation.14 Pain is a common cause of agitation in dementia, occurring in 57% of patients, and pain resolution can improve agitation.15 A 3 Rs approach (repeat, reassure, redirect) is recommended.14 In severe aggression that threatens the safety of the patient or others, use atypical antipsychotics to target symptoms without sedating the patient.16 The lowest effective dose should be used for the shortest time. A deprescribing algorithm is available.16
Notes
Tools for Practice articles in Canadian Family Physician are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in Canadian Family Physician are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.
Footnotes
Competing interests
None declared
The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.
This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to www.cfp.ca and click on the Mainpro+ link.
La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de mai 2018 à la page e232.
- Copyright© the College of Family Physicians of Canada